中心性肥胖与接受抗病毒治疗的慢性乙型肝炎患者肝细胞癌风险相关
本研究基于中国多中心前瞻性观察性接受抗病毒治疗的慢性乙型肝炎队列,纳入5754例核苷(酸)类似物治疗患者,评估肥胖对肝细胞癌(HCC)发生的影响。中位随访5年累积HCC发病率为2.9%,腰高比预测HCC优于BMI、腰围或腰臀比;中心性肥胖(腰高比>0.5)患者5年HCC累积发病率显著高于无中心性肥胖者(3.9% vs 2.1%,HR 2.06,P=0.0001)。中心性肥胖是HCC独立危险因素(HR 1.63,P=0.013),且1年内腰高比增加与HCC风险升高相关(aHR 1.88,95%CI 1.12-3.13,P=0.017)。
要点
- 中心性肥胖(腰高比>0.5)使抗病毒治疗的CHB患者HCC风险约增2倍。
- 腰高比预测HCC优于BMI、腰围和腰臀比。
- 1年内腰高比增加与HCC风险升高独立相关。
核心结论
- 以腰高比评估的中心性肥胖与接受抗病毒治疗的CHB患者HCC风险增加约2倍相关,提示代谢异常在肝病进展中的作用。
研究设计与样本
- 中国多中心、前瞻性、观察性接受治疗的CHB队列研究,共纳入5754例核苷(酸)类似物治疗患者。
主要发现
- 5年HCC累积发病率为2.9%。
- 中心性肥胖(腰高比>0.5)患者5年HCC发病率显著高于无中心性肥胖者(3.9% vs 2.1%,HR 2.06,P=0.0001)。
- 在745对倾向性评分匹配患者中,中心性肥胖者5年HCC发病率亦显著更高(4.7% vs 2.3%,HR 2.04,P=0.026)。
- 中心性肥胖是HCC独立危险因素(HR 1.63,P=0.013)。
- 1年内腰高比增加与HCC风险升高相关(aHR 1.88,95%CI 1.12-3.13,P=0.017)。
关键数值与推荐
- 中心性肥胖定义为腰高比>0.5。
- 腰高比预测HCC优于BMI、腰围或腰臀比。
临床怎么用
- 对接受抗病毒治疗的CHB患者,应评估腰高比以识别中心性肥胖及HCC高风险人群。
- 动态监测腰高比变化可能有助于HCC风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is typically associated with metabolic dysfunction, but its impact on hepatocellular carcinoma (HCC) remains unclear in patients with chronic hepatitis B (CHB). AIM: To study the effect of obesity on HCC development in patients with CHB receiving antiviral therapy. METHODS: We included patients from a Chinese multicentre, prospective, observational, treated CHB cohort in this study. General obesity was evaluated by body-mass index (BMI). Central obesity was evaluated by waist circumference, waist-to-hip ratio and waist-to-height ratio. RESULTS: A total of 5754 nucleos(t)ide analogue treated patients were enrolled in the analysis. The 5-year cumulative incidence of HCC was 2.9%. Waist-to-height ratio performed better in predicting HCC development than BMI, waist circumference or waist-to-hip ratio. Patients with central obesity (defined as waist-to-height ratio >0.5) had significantly higher 5-year incidence of HCC than those without central obesity in the overall population (3.9% vs 2.1%, hazard ratio [HR]: 2.06, P = 0.0001) and 745 propensity score matched pairs (4.7% vs 2.3%, HR: 2.04, P = 0.026), respectively. Besides cirrhosis status and aMAP HCC risk score, central obesity was also independently associated with HCC risk (HR: 1.63, P = 0.013). Waist-to-height ratio gain within 1 year was associated with a significantly higher HCC risk with an adjusted HR value of 1.88 (95% confidence interval: 1.12-3.13, P = 0.017). CONCLUSIONS: Central obesity, evaluated by the waist-to-height ratio, was associated with a twofold increase in HCC risk among CHB patients receiving antiviral treatment, highlighting the important role of abnormal metabolic function in the progression of liver disease.
引用
- Fan R, Niu J, Ma H, et al. Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy. Aliment Pharmacol Ther. 2021. PMID: 34157146. doi:10.1111/apt.16469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。